Akcea Therapeutics Inc (AKCA) Stock News
NASDAQ:AKCA - Nasdaq -
AKCA Latest News, Press Relases and Analysis
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
Mentions: IONS
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
Transaction creates a stronger, more efficient company
Mentions: IONS
Ionis' Alexander Disease Candidate Gets Orphan Drug Status
The FDA assigns an orphan drug designation to Ionis' (IONS) pipeline candidate ION373 for treating patients with Alexander disease.
SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Investigations
Mentions: IMMU
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Is Investigating the Following Companies; Shareholders are Encouraged to Contact the Firm – CGIX, BYFC, BMCH, AKCA
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Cancer Genetics, Inc. (NASDAQ: CGIX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with StemoniX, Inc. Under the merger agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX in exchange for a number of shares
Moore Kuehn Encourages RST, AKCA, DCOM, and SBPH Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, AKCA, VRTU, IMMU
NEW YORK, NY / ACCESSWIRE / September 21, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. Under the terms of the merger, Cellular Biomedicine
Akcea's Waylivra secures NICE recommendation for ultra-rare inherited disorder (NASDAQ:AKCA)
Akcea Therapeutics (NASDAQ:AKCA), majority-owned affiliate of Ionis Pharmaceuticals (NASDAQ:IONS) announces that the National Institute for Health and Care Excellence (NICE) has issued a positive Final Evaluation Document for WAYLIVRA (volanesorsen) for the treatment of Familial Chylomicronaemia Syndrome (FCS) for routine care on the National Health Service in England.FCS a rare, inherited disorder characterised by impaired clearance of triglyceride-rich lipoproteins from plasma, leading to severe hypertriglyceridaemia and a markedly increased risk of acute pancreatitis.Volanesorsen is the first and only treatment for FCS currently available in the UK.
Mentions: IONS
Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis
Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.
ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm – AIMT, AKCA, PTI
NEW YORK, NY / ACCESSWIRE / September 12, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sociétés des Produits Nestlé, S.A. for $34.50 per share. To learn more about your legal rights and options, visit:
SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA and AIMT Shareholders About Its Ongoing Investigations
Mentions: AIMT
INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, Inc. - AKCA
Ionis to Acquire Remaining Stake in Akcea, Stocks Rally
Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.
Benzinga's Top Upgrades, Downgrades For September 1, 2020
Upgrades For Qualcomm Inc (NASDAQ: QCOM), Wells Fargo upgraded the previous rating of Underweight to the current rating Equal-Weight. For the third quarter, Qualcomm had an EPS...
10 Biggest Price Target Changes For Tuesday
Goldman Sachs raised the price target for Zoom Video Communications Inc (NASDAQ: ZM) from $187 to $402. Zoom Video shares rose 30% to $422.51 in pre-market trading. Wells Fargo...
(AKCA) Alert: Johnson Fistel Investigates Proposed Sale of Akcea Therapeutics; Is $18.15 a Fair Price?
Mentions: IONS
SHAREHOLDER ALERT: WeissLaw LLP Investigates Akcea Therapeutics, Inc.
Mentions: IONS
Why Akcea Therapeutics Stock Skyrocketed Today
The biotech is being acquired by its largest shareholder.
Mentions: IONS
GTX, GME, GNW and AIMT among midday movers
Gainers: Aimmune Therapeutics (NASDAQ:AIMT) +171%.Akcea Therapeutics (NASDAQ:AKCA) +60%.Genworth Financial (NYSE:GNW) +29%.Color Star Technology (NASDAQ:HHT) +25%.GameStop (NYSE:GME) +24%.Kindred Biosciences (NASDAQ:KIN) +20%.Atomera Incorporated (NASDAQ:ATOM) +18%.ChinaNet Online Holdings (NASDAQ:CNET) +18%.AutoWeb (NASDAQ:AUTO) +16%.Neuronetics (NASDAQ:STIM) +17%.Losers: Shiloh Industries (NASDAQ:SHLO) -63%.
Aimmune Therapeutics rallies on Nestle acquiring, Akcea cheers Ionis acquiring 24% remaining stake, ADiTx Therapeutics and Lipocine among major losers
Gainers: Aimmune Therapeutics (NASDAQ:AIMT) +172%, Akcea Therapeutics (NASDAQ:AKCA) +60%, Pro-Dex (NASDAQ:PDEX) +16%, Kindred Biosciences (NASDAQ:KIN) +14%, Neuronetics (NASDAQ:STIM) +11%.Losers: ADiTx Therapeutics (NASDAQ:ADTX) -11%, Lipocine (NASDAQ:LPCN) -11%, Orchard Therapeutics (NASDAQ:ORTX) -11%, CNS Pharmaceuticals (NASDAQ:CNSP) -9%, Anchiano Therapeutics (NASDAQ:ANCN) -8%.
Akcea shoots up 59% after Ionis acquires remaining stake for $500M; positive vupanorsen data reported (NASDAQ:AKCA)
Akcea Therapeutics (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals (NASDAQ:IONS) presents data from the Phase 2 clinical trial of vupanorsen (AKCEA-ANGPTL3-LRx) at the ESC Congress 2020.Vupanorsen, an investigational antisense therapy being developed using Ionis' Ligand Conjugated Antisense technology platform to reduce the production of angiopoietin-like 3 (ANGPTL3) protein from the liver which is a key regulator of triglyceride and cholesterol metabolism is used to treat patients with certain cardiovascular diseases.In the Phase 2 study, vupanorsen met the primary endpoint of significant reductions in triglyceride (TG) levels and multiple secondary endpoints compared to placebo, with a favorable safety and tolerability profile.A total of 105 patients with hypertriglyceridemia (fasting plasma TG levels >150 mg/dL), type 2 diabetes and non-alcoholic fatty liver disease were randomized to three dosing cohorts in a 3:1 ratio (vupanorsen:placebo) within each cohort and treated for six months.Statistically significant dose-dependent reductions in fasting TGs at all dose levels, with the highest mean reduction of 53% at 80 mg every four weeks (44% mean reduction compared to placebo, P<0.0001).Statistically significant dose-dependent reductions compared to placebo in ANGPTL3 (62%), very low-density lipoprotein (VLDL) cholesterol (38%), total cholesterol (19%), and non-high-density lipoprotein (non-HDL) cholesterol (18%) (mean reductions achieved with the 80 mg every four-week dose).No effect on glycemic parameters and no decrease in hepatic steatosis and a favorable tolerability and safety profile was observed.Also, IONS and AKCA have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares of Akcea common stock, not already owned, ~24%, for $18.15/share in cash, for the total transaction value of ~$500M.As on June 2020, AKCA had a total 101.5M common shares outstanding. AKCA is up 59% premarket.
Mentions: IONS
Akcea shoots up 59% on positive vupanorsen data; Ionis acquires remaining stake for $500M (NASDAQ:AKCA)
Akcea Therapeutics (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals (NASDAQ:IONS) presents data from the Phase 2 clinical trial of vupanorsen (AKCEA-ANGPTL3-LRx) at the ESC Congress 2020.Vupanorsen, an investigational antisense therapy being developed using Ionis' LIgand Conjugated Antisense technology platform to reduce the production of angiopoietin-like 3 (ANGPTL3) protein from the liver which is a key regulator of triglyceride and cholesterol metabolism is used to treat patients with certain cardiovascular diseases.In the Phase 2 study, vupanorsen met the primary endpoint of significant reductions in triglyceride (TG) levels and multiple secondary endpoints compared to placebo, with a favorable safety and tolerability profile.A total of 105 patients with hypertriglyceridemia (fasting plasma TG levels >150 mg/dL), type 2 diabetes and non-alcoholic fatty liver disease were randomized to three dosing cohorts in a 3:1 ratio (vupanorsen: placebo) within each cohort and treated for six months.Statistically significant dose-dependent reductions in fasting TGs at all dose levels, with the highest mean reduction of 53% at 80 mg every four weeks (44% mean reduction compared to placebo, P<0.0001).Statistically significant dose-dependent reductions compared to placebo in ANGPTL3 (62%), very low-density lipoprotein (VLDL) cholesterol (38%), total cholesterol (19%), and non-high-density lipoprotein (non-HDL) cholesterol (18%) (mean reductions achieved with the 80 mg every four week dose).No effect on glycemic parameters and no decrease in hepatic steatosis and a favorable tolerability and safety profile was observed.Also, IONS and AKCA have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares of Akcea common stock, not already owned, ~24%, for $18.15/share in cash, for the total transaction value of ~$500M.As on June 2020, AKCA had a total 101.5M common shares outstanding. AKCA is up 59% premarket.
Mentions: IONS